Vyteris to Present at the Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on February 17 by EON

VIEWS: 13 PAGES: 2

More Info
									Vyteris to Present at the Lippert/Heilshorn Life
Sciences & Medical Technologies Virtual
Conference on February 17
February 16, 2011 08:03 AM Eastern Time 

FAIR LAWN, N.J.--(EON: Enhanced Online News)--Vyteris, Inc. (OTCBB: VYTR), an innovator in alternative
drug delivery technology, announces that Haro Hartounian, Ph.D., President and Chief Executive Officer of Vyteris,
will deliver a corporate presentation as part of the Lippert/Heilshorn & Associates Life Sciences & Medical
Technologies On-Line Forum on Thursday, February 17, 2011 at 10:00 a.m. Eastern time.

Dr. Hartounian will provide an overview of the Company and its proprietary smart patch technology, as well as an
update on the company's strategic merger with MediSync BioServices, Inc., a consolidator of contract research and
site management organizations.

A live webcast of the presentation will be accessible online at the PrecisionIR event site:
http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=163285 as well as on the Company’s website at
www.vyteris.com. An archived version will be available for 30 days on both sites.

About Vyteris

Vyteris, Inc. is the maker of the first active, ready-to-use drug delivery patch (LidoSite®) to receive marketing
clearance from the U.S. Food and Drug Administration. Vyteris' proprietary active transdermal smart patch
technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart
patch technology is intended to allow precise dosing, giving physicians and patients control in the rate, dosage and
pattern of drug delivery that may result in considerable therapeutic, economic, and lifestyle advantages over existing
methods of drug administration. Vyteris has successfully delivered a peptide non-invasively using its system, where
the Company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more
information, please visit www.vyteris.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the
United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project,"
"anticipate," "intend," "plan," "may," "will," "could," "would," "should," "believes," and similar expressions are intended
to identify such forward-looking statements. Forward-looking statements in this press release include, without
limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve
known and unknown risks, uncertainties and other factors that may cause actual results, performance or
achievements to differ materially from results expressed or implied by this press release. Such risk factors include,
among others, the competitive environment and competitive responses to the new marketing arrangement. The
Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent
Annual Report on Form 10-K and in various filings made with the SEC. Actual results may differ materially from
those contained in the forward-looking statements in this press release.

Contacts
Vyteris, Inc.
Joseph Himy, Chief Financial Officer
(201) 703-2299
investorrelationis@vyteris.com
or
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields, Senior Vice President
(212) 838-3777
afields@lhai.com

Permalink: http://eon.businesswire.com/news/eon/20110216005458/en

								
To top